BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
05/04/2021
Initial Lawsuit
05/13/2021
Lawsuit Progression
08/10/2021
Settlement
05/04/2022
Investigation in connection with Aterian’s (formerly Mohawk Group Holdings, Inc.) recent acquisitions, ‘AIMEE’ platform and allegations of ties to “convicted criminals.”
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
05/04/2021
Culper Research publishes a ‘short’ report alleging that the company’s organic growth is plummeting, the company has ties to “convicted criminals” and is promoting a “overhyped ‘AI’ narrative a string of garbage acquisitions to mask the failure of its already ill-conceived core business.“
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$17.62 | $20.66 | $-3.04 | -14.71% |
This is a federal securities class action on behalf of all investors who purchased orotherwise acquired Aterian, Inc. (formerly known as Mohawk Group Holdings, Inc.) securities between December 1, 2020 and May 3, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) the company’s organic growth is plummeting;
(ii) the company’s recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources;
(iii) Aterian’s purported artificial intelligence software is a flawed product that lacks customer interest;
(iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings;
(v) as a result, the company’s public statements were materially false and misleading at all relevant times.
08/10/2021
The court issued an order appointing the lead plaintiff and lead counsel.
10/14/2021
This is a federal securities class action on behalf of a class consisting of all persons other than defendants who purchased the common stock of Aterian, Inc. between December 1, 2020 and May 3, 3021, both dates inclusive.
Additional amended complaints have been filed, please refer to the last filed amended complaint for up-to-date information.
11/03/2021
This is a federal securities class action on behalf of a class consisting of all persons other than defendants who purchased the common stock of Aterian, Inc. between December 1, 2020 and May 3, 3021, both dates inclusive.
Additional amended complaints have been filed, please refer to the last filed amended complaint for up-to-date information.
01/05/2022
This is a federal securities class action on behalf of a class consisting of all persons other than defendants who purchased the common stock of Aterian, Inc. between December 1, 2020 and May 3, 3021, both dates inclusive. *See notice of settlement of extension to 8/24/2020.
Operative complaint
On 05/04/2022, lead counsel The Rosen Law Firm, P.A. announced a proposed class action settlement.
The court preliminarily approved the settlement on 05/05/2022. The settlement has a total value of $1,300,000 in Cash.
The notice states that you may be included, if you purchased or otherwise acquired the company’s publicly traded common stock during the period from 08/24/2020 to 05/03/2021, inclusive.
According to the notice, the estimated average cash recovery per damaged share of common stock will be approximately $0.36 per share, before deduction of court-approved fees and expenses. Lead Counsel filed a motion for an award of attorneys’ fees not to exceed 33% of the $1,300,000 and payment of expenses not to exceed $40,000.
For information purposes only, last updated on 06/08/2022. Contact the claims administrator or lead counsel for further information.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.